Endomorphin-1

What is Endomorphin-1?

Endomorphin-1 (EM-1) is a four-residue endogenous opioid peptide with the sequence Tyr-Pro-Trp-Phe-NH2 (YPWF-amide) and a C-terminal amide rather than a free carboxyl. It was isolated from bovine brain by James Zadina, Laszlo Hackler, Lin-Jun Ge, and Abba Kastin at Tulane University and reported in Nature in 1997, in the same paper that introduced its sister peptide endomorphin-2 (Tyr-Pro-Phe-Phe-NH2). The two endomorphins share the unusual Tyr-Pro N-terminus and differ only in the third position. They are pharmacologically extraordinary on two counts: they are the most selective endogenous mu-opioid receptor (MOR) agonists ever identified, with affinity for MOR more than 1000-fold higher than for the delta- or kappa-opioid receptors; and they bind MOR with an affinity comparable to morphine despite being chemically unrelated to the classical YGGFL/YGGFM opioid pharmacophore that opens the enkephalins, beta-endorphin, and the dynorphins. Where every other vertebrate endogenous opioid peptide begins with the canonical Tyr-Gly-Gly-Phe motif, the endomorphins begin with Tyr-Pro — a structural anomaly that has shaped four decades of speculation about their evolutionary origin and biosynthetic pathway. Functionally, EM-1 produces potent analgesia, slowed gastrointestinal transit, modest cardiovascular effects, and the standard suite of mu-opioid responses when administered exogenously to animal models. Despite the discovery, the precursor protein and gene that would yield endomorphin-1 by proteolytic processing have never been definitively identified, and Anna Terskiy and colleagues argued in a 2007 Life Sciences paper that no plausible endomorphin precursor exists in the human proteome — a finding that has kept the formal endogenous status of the endomorphins under contested debate while doing little to dampen interest in their unusual receptor pharmacology. Endomorphin-1 itself is not a drug. The translational interest centers on stabilized analogs (cyclic, lipidized, fluorinated, halogenated, and all-D constructs, particularly the ZH-series from the Zadina laboratory) being developed as preclinical analgesics with reduced respiratory depression, tolerance, and abuse liability relative to morphine.

What Endomorphin-1 Is Investigated For

Endomorphin-1 is an endogenous-pharmacology and drug-discovery topic, not a peptide consumers take. Its scientific importance comes from three intersecting facts. First, the 1997 Zadina Nature paper introduced what remains the most mu-opioid-selective endogenous agonist family ever identified — by orders of magnitude more selective than beta-endorphin or the enkephalins for MOR over delta and kappa receptors, with full-agonist efficacy and morphine-comparable affinity. Second, the structural anomaly: every other endogenous opioid peptide opens with Tyr-Gly-Gly-Phe, the canonical pharmacophore that defines the enkephalin family. The endomorphins instead use Tyr-Pro-Trp/Phe-Phe-NH2, a chemically distinct N-terminus that engages MOR through a different binding pose and that has resisted clear evolutionary placement. Third, the unresolved precursor question: despite an intensive search of mammalian genomes and proteomes, no convincing precursor protein or gene has been identified that would yield Tyr-Pro-Trp-Phe-NH2 by canonical proteolytic processing — the Terskiy 2007 Life Sciences proteome search was negative, and alternative biosynthetic pathways (non-ribosomal synthesis, unusual processing of an unidentified parent) remain speculative. Whatever the resolution, the pharmacology has driven a sustained drug-discovery effort. Native EM-1 has poor pharmacokinetics — rapid degradation by dipeptidyl peptidase IV and other peptidases, limited blood-brain-barrier penetration — but stabilized analogs developed primarily by the Zadina group at Tulane (the ZH-series, including ZH853 and related cyclic and lipidized constructs) have shown analgesic efficacy in neuropathic, inflammatory, postoperative, and visceral pain models with reduced respiratory depression, tolerance, motor impairment, and abuse liability relative to morphine. Other groups (Lipkowski, Janecka, Cardillo, Spetea, Tóth) have explored mixed-agonist endomorphin analogs and biased-signaling probes. As of 2026, no endomorphin-derived analgesic has reached approval; the work is preclinical and early translational. The honest framing is that endomorphin-1 is one of the most pharmacologically distinctive endogenous peptides in the opioid system — and one of the most enduring unsolved puzzles in opioid biochemistry.

History & Discovery

Endomorphin-1 and endomorphin-2 were reported in Nature in 1997 by James E. Zadina, Laszlo Hackler, Lin-Jun Ge, and Abba J. Kastin at the Tulane University School of Medicine and the Veterans Affairs Medical Center in New Orleans. The Zadina-Kastin laboratory had spent years searching for endogenous mu-opioid receptor agonists with selectivity beyond what beta-endorphin and the enkephalins provided, using bioassay-guided purification of bovine brain extracts at the cloned mu receptor. The result was the isolation of two four-residue peptides — Tyr-Pro-Trp-Phe-NH2 (endomorphin-1) and Tyr-Pro-Phe-Phe-NH2 (endomorphin-2) — that bound MOR with affinity comparable to morphine and selectivity for MOR over delta and kappa receptors of more than 1000-fold and several hundred-fold respectively. The Nature paper introduced the endomorphins as the most selective endogenous mu-opioid agonists ever identified and gave the field its first chemically distinct class of endogenous opioid peptide outside the canonical YGGFL enkephalin family. The Hackler, Kastin, Erchegyi, and Zadina 1997 Peptides paper followed up by detecting and quantifying endomorphin-1 and endomorphin-2 in human cerebral cortex, extending the bovine-brain isolation to human tissue. Within months of the original Nature paper, several laboratories reported on the in vivo pharmacology of the new peptides: Champion, Zadina, Kastin, Hackler, and Kadowitz reported novel hypotensive and vasodilator effects in the rabbit and rat (BBRC 1997 and Life Sciences 1997), Goldberg et al. reported antinociceptive efficacy by spinal and supraspinal administration, and Stone, Fairbanks, Laughlin, and Wilcox documented analgesic potency comparable to morphine in spinal cord paradigms. Anatomical mapping followed in the Martin-Schild, Gerall, Kastin, and Zadina 1999 Journal of Comparative Neurology paper, which established the partially distinct distributions of EM-1 (broadly throughout the brain) and EM-2 (concentrated in lower brainstem and spinal cord, enriched in primary afferent fibers) — an anatomical signature that has remained the reference framework for endomorphin distribution work. The precursor question opened almost immediately. The endomorphins begin with Tyr-Pro rather than the canonical Tyr-Gly-Gly-Phe of the enkephalin family, and no precursor gene or protein could be identified that would yield Tyr-Pro-Trp-Phe-NH2 or Tyr-Pro-Phe-Phe-NH2 by canonical proteolytic processing. Anna Terskiy, Wannemacher, Yadav, Tsai, Tian, and Howells published a systematic search of the human proteome in Life Sciences 2007 and reported no plausible precursor — a finding that has been the principal challenge to the formal endogenous status of the endomorphins. Alternative interpretations — non-ribosomal biosynthesis, processing of an unidentified parent protein, or possible cross-reactivity in immunohistochemistry — have been discussed but not resolved. The contested status has not affected work on the synthetic peptides at MOR, which is unambiguous and reproducible. The medicinal-chemistry program around stabilized endomorphin analogs began in the late 1990s and continues into the 2020s. Cyclic analogs (Cardillo, Lipkowski, and others), lipidized analogs (Varamini and colleagues 2013 Bioorganic and Medicinal Chemistry), fluorinated and halogenated constructs, all-D and N-methylated peptides, and mixed-pharmacology hybrids (mu-agonist/delta-antagonist designs from Schiller and colleagues, including the work reported in Bioorganic and Medicinal Chemistry 2014) have all been explored. The most advanced preclinical line is the Zadina laboratory's ZH-series, anchored by ZH853, which a 2016 Neuropharmacology paper compared head-to-head with morphine in rats and showed morphine-comparable analgesia with reduced respiratory depression, motor impairment, tolerance, glial activation, and self-administration. Subsequent papers (J Pain 2017, Pain Medicine 2020, J Pain 2024) have extended the ZH853 efficacy profile across neuropathic, inflammatory, postoperative, visceral, and immunomodulatory contexts. The comprehensive Fichna, Janecka, Costentin, and Do Rego review in Pharmacological Reviews 2007 remains the principal field overview through the mid-2000s; the more recent work has been summarized in field-specific reviews on endomorphin analogs and mu-opioid biased agonism. As of 2026, no endomorphin-derived analgesic has reached approval, and the formal endogenous-precursor question remains unresolved.

How It Works

Endomorphin-1 is a tiny four-amino-acid protein that fits, like a key, into the brain's mu-opioid receptor — the same receptor that morphine and other classical opioids activate. When endomorphin-1 binds, the cell's signaling machinery turns down nerve activity in pain circuits, which produces analgesia. What makes endomorphin-1 unusual is its precision: it ignores the other two opioid receptors (delta and kappa) almost completely and goes straight for mu, more selectively than any other natural opioid peptide ever found. That extreme selectivity, plus its small size, make it a useful starting structure for designing pain medications that keep the analgesic benefits of morphine while reducing side effects like respiratory depression and addiction risk. Native endomorphin-1 itself breaks down too quickly to be a drug, but chemists have built stabilized versions that survive long enough to work — and in animal studies these survive their first big test, producing morphine-strength pain relief with less of the dangerous baggage.

Endomorphin-1 (Tyr-Pro-Trp-Phe-NH2, EM-1) is a four-residue endogenous opioid peptide reported by Zadina, Hackler, Ge, and Kastin in Nature 1997 alongside its sister peptide endomorphin-2 (Tyr-Pro-Phe-Phe-NH2, EM-2). The two peptides were isolated from bovine brain by bioassay-guided purification and confirmed in human cortical tissue. Both terminate in a C-terminal amide rather than a free carboxyl — a post-translational modification that is common in bioactive peptides and that contributes to receptor binding and metabolic stability. The defining structural feature is the Tyr-Pro N-terminus, which is shared with the exogenous frog-skin opioid peptides dermorphin and deltorphin but is otherwise unique among vertebrate endogenous opioid peptides; every other family member (Met- and Leu-enkephalin, beta-endorphin, dynorphin A and B, alpha- and beta-neo-endorphin) begins with the canonical Tyr-Gly-Gly-Phe (YGGF) opioid pharmacophore. The endomorphins thus represent a chemically distinct class within the endogenous opioid peptide system. Receptor pharmacology is extreme. Endomorphin-1 binds the mu-opioid receptor (MOR, encoded by OPRM1) with affinity in the low nanomolar range and selectivity for MOR over the delta-opioid receptor (DOR/OPRD1) and kappa-opioid receptor (KOR/OPRK1) of more than 1000-fold and several hundred-fold respectively — a selectivity profile that exceeds beta-endorphin (modestly mu-preferring) and the enkephalins (delta-preferring) by orders of magnitude. EM-1 is a full agonist at MOR, with intrinsic activity comparable to morphine and DAMGO in standard assays of G-protein coupling, cAMP inhibition, and inwardly-rectifying potassium channel activation. MOR is a Gi/o-coupled GPCR that, on activation, inhibits adenylate cyclase and lowers cAMP, hyperpolarizes neurons through GIRK channel activation, and inhibits voltage-gated calcium channels at presynaptic terminals — the canonical MOR signaling cascade that underlies opioid analgesia, respiratory depression, gastrointestinal slowing, and reward. Anatomically, endomorphin-1-like and endomorphin-2-like immunoreactivity has been mapped extensively by Martin-Schild, Gerall, Kastin, and Zadina (Journal of Comparative Neurology 1999) and by other groups. EM-1 immunoreactivity is broadly distributed throughout the brain, with prominent expression in cerebral cortex, striatum, nucleus accumbens, thalamus, hypothalamus, periaqueductal gray, locus coeruleus, parabrachial nucleus, and several brainstem nuclei. EM-2 immunoreactivity is more concentrated in lower brainstem and spinal cord dorsal horn and is enriched in primary afferent sensory fibers (Martin-Schild et al. 1998 Peptides; Pierce et al. 1998), consistent with a role in spinal nociceptive transmission. The differential distribution suggests partially distinct functional roles within the endomorphin/MOR system. Functionally, exogenous endomorphin-1 produces potent supraspinal and spinal analgesia in rodent and primate models, with characteristic mu-opioid responses including sedation, slowed gastrointestinal transit, transient hypotension and bradycardia (Champion et al. 1997 BBRC), and respiratory depression. Tolerance develops with repeated administration. Native EM-1 has poor pharmacokinetics: it is rapidly degraded by dipeptidyl peptidase IV (which cleaves the Tyr-Pro N-terminus), aminopeptidase, and other peptidases, with a plasma half-life on the order of minutes, and it has limited blood-brain-barrier penetration as an unmodified peptide. These limitations have driven the medicinal-chemistry program around stabilized endomorphin analogs — cyclic constructs (Cardillo, Lipkowski, and others), lipidized analogs (Yamamoto et al. 2008; Varamini et al. 2013 lipo-endomorphin-1 series), fluorinated and halogenated analogs, mixed mu-agonist/delta-antagonist analogs (Schiller and colleagues), and the ZH-series from the Zadina group at Tulane, which includes ZH853 and related compounds shown in a 2016 Neuropharmacology paper and subsequent work to produce morphine-comparable analgesia in neuropathic, inflammatory, postoperative, and visceral pain models with reduced respiratory depression, tolerance, motor impairment, glial activation, and self-administration. Some of these analogs show evidence of biased agonism at MOR — preferential activation of G-protein signaling over beta-arrestin-2 recruitment — providing a possible molecular basis for the separation of analgesic from respiratory and abuse effects.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Endomorphin-1:

• 01Whether a precursor protein and gene exist that produce endomorphin-1 by canonical or non-canonical biosynthesis — the unresolved question that has hung over the field since the 1997 Nature paper, with the Terskiy 2007 proteome search returning a negative result and no compelling alternative precursor identified since.
• 02Whether endomorphin-like immunoreactivity in mammalian central nervous system reflects authentic endomorphin-1 and endomorphin-2 in vivo, or whether at least some of the signal could reflect cross-reactivity of antibodies with structurally related peptides — a question that the unresolved precursor issue has kept open.
• 03Whether the analgesic-versus-respiratory-depression separation seen with stabilized endomorphin analogs in rodents (the ZH-series) will translate to human pharmacology, and whether that separation is mediated by biased agonism at MOR (G-protein over beta-arrestin), by altered receptor compartment selectivity, or by other mechanisms.
• 04Whether stabilized endomorphin analogs will ultimately demonstrate reduced abuse liability in human studies — the rodent self-administration data are encouraging but historically have not always predicted human abuse-liability outcomes for opioid molecules.
• 05Whether endomorphin-1 and endomorphin-2 serve genuinely distinct functional roles given their partially distinct anatomical distributions, or whether the two peptides are largely redundant variants of a single mu-opioid signaling system.
• 06The role of endomorphin-1 in cardiovascular regulation, neuroendocrine function, and immune modulation — domains where rodent pharmacology has identified effects but where physiological significance and translational relevance remain underdeveloped.
• 07Whether mixed-pharmacology endomorphin analogs (mu-agonist/delta-antagonist, mu-agonist/NK1-antagonist, biased-signaling constructs) will outperform single-target analogs as analgesic candidates, and which of the multiple medicinal-chemistry strategies (cyclic, lipidized, fluorinated, all-D) will prove most translatable.

Forms & Administration

Endomorphin-1 is not formulated or approved as a therapeutic in any jurisdiction. Research applications use synthetic endomorphin-1 (Tyr-Pro-Trp-Phe-NH2) for in vitro receptor binding and signaling assays at cloned and native MOR, ex vivo bioassays (guinea pig ileum, mouse vas deferens), and intracerebroventricular, intrathecal, or intravenous administration in animal models. Native EM-1 is unsuitable for systemic administration because of rapid peptidase degradation and poor blood-brain-barrier penetration. Drug-discovery efforts focus on stabilized analogs: cyclic peptides (constraining the conformation against peptidase access), lipidized analogs (improving bioavailability and BBB penetration), fluorinated and halogenated analogs, all-D and N-methylated constructs, and mixed-pharmacology hybrids (mu-agonist/delta-antagonist or mu-agonist/NK1-antagonist designs). The Zadina laboratory's ZH-series (ZH853 and related compounds) is the most advanced preclinical line, with intravenous and other parenteral routes used in rodent neuropathic, inflammatory, postoperative, and visceral pain models. None of these analogs has reached approval. Compounded endomorphin-1 from peptide marketplaces has no validated clinical use, and native EM-1 from any source would be expected to be largely inactive after typical consumer routes of administration.

Common Questions

Who Endomorphin-1 Is NOT For

Drug & Supplement Interactions

There is no validated human drug-interaction profile for endomorphin-1 because no endomorphin product has been clinically developed. Theoretical interactions follow from mu-opioid receptor pharmacology. Combination with other mu-opioid agonists (morphine, oxycodone, hydrocodone, fentanyl, methadone, buprenorphine, tramadol) would produce additive analgesia, sedation, and respiratory depression. Combination with central nervous system depressants — benzodiazepines, barbiturates, gabapentinoids, alcohol, sedating antihistamines — would amplify respiratory depression and sedation, the same dangerous interaction class that drives prescription-opioid mortality. Combination with mu-opioid antagonists or partial agonists (naloxone, naltrexone, buprenorphine) would block or reduce endomorphin-1 effects. Serotonergic interactions are theoretically possible with serotonin reuptake inhibitors and MAOIs, particularly given the propensity for some opioids (notably tramadol and meperidine) to participate in serotonin syndrome, though endomorphin-1 itself has no documented direct serotonergic pharmacology. Endomorphin-1 is rapidly degraded by dipeptidyl peptidase IV, so co-administration with DPP-IV inhibitors used in type 2 diabetes (sitagliptin, linagliptin, saxagliptin, alogliptin) could in principle prolong endomorphin-1 exposure, though the clinical relevance is unestablished. None of these interactions has been characterized in controlled human studies; they are mechanistic predictions from MOR pharmacology rather than documented clinical events.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions